Survival and cardiovascular pathology of heterozygous Watanabe heritable hyperlipidaemic rabbits treated with pravastatin and probucol on a low-cholesterol (0.03%)-enriched diet

Virchows Archiv

Volumn 432, Issue 6, 1998, Pages 557-562

  Bräsen, Jan Hinrich ^a   Harsch, Michael ^a   Niendorf, Axel ^a,b  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b Gemeinschaftspraxis F Pathologie   (Germany)

Author keywords

Atherosclerosis; Morphometric analysis; Pathology; Pravastatin; Probucol; Survival; WHHL rabbits

Indexed keywords

CHOLESTEROL; LIPID; PRAVASTATIN; PROBUCOL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA; ARTICLE; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL INTAKE; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; DRUG EFFICACY; EXTRACELLULAR MATRIX; FEMALE; FOAM CELL; HETEROZYGOTE; HYPERLIPIDEMIA; MALE; NONHUMAN; PRIORITY JOURNAL; SURVIVAL;

ANIMALS; AORTA; CHOLESTEROL; CHOLESTEROL, DIETARY; CORONARY ARTERIOSCLEROSIS; DRUG THERAPY, COMBINATION; FEMALE; HYPERLIPIDEMIAS; IMMUNOHISTOCHEMISTRY; LIVER; MALE; PRAVASTATIN; PROBUCOL; RABBITS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0031835357     PISSN: 09456317     EISSN: None     Source Type: Journal    
DOI: 10.1007/s004280050205     Document Type: Article

References (35)

1. Anderson TD, Meredith IT, Yeung AC, Frei B, Selwyn AP, Ganz P (1995) The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. N Engl J Med 332:488-493
2. Atkinson JB, Swift LL, Virmani R (1992) Animal model of human disease: Watanabe heritable hyperlipidemic rabbits. Am J Pathol 140:749-753
3. Atkinson JB, Hoover RL, Berry KK, Swift LL (1989) Cholesterol-fed heterozygous Watanabe heritable hyperlipidemic rabbits: a new model for atherosclerosis. Atherosclerosis 78:123-136
4. Braesen JH, Beisiegel U, Niendorf A (1995) Probucol inhibits not only the progression of atherosclerotic disease, but causes a different composition of atherosclerotic lesions in WHHL rabbits. Virchows Arch 426:179-188
5. Brown BG, Zhao XQ, Sacco DE, Albers JJ (1993) Lipid lowering and plaque regression. New insights into prevention of plaque disruption and clinical events in coronary disease. Circulation 87:1781-1791
6. Buja LM, Kita T, Goldstein JL, Watanabe Y, Brown MS (1983) Cellular pathology of progressive atherosclerosis in the WHHL rabbit. An animal model of familial hypercholesterolemia. Arteriosclerosis 3:87-101
7. Carew TE, Schwenke DC, Steinberg D (1987) Antiatherogenic effect of Probucol unrelated to its hypocholesterolemic effect: evidence that antioxidants in vivo can selectively inhibit low density lipoprotein degradation in macrophage-rich fatty streaks and slow the progression of atherosclerosis in the Watanabe heritable hyperlipidemic rabbit. Proc Natl Acad Sci USA 84:7725-7729
8. Corsini A, Raiteri M, Soma M, Fumagalli R, Paoletti R (1991) Simvastatin but not pravastatin inhibits the proliferation of rat aorta myocytes. Pharmacol Res 23:173-180
9. Doherty TM, Detrano RC (1994) Coronary arterial calcification as an active process: a new perspective on an old problem. Calcif Tissue Int 54:224-230
10. Esper E, Chan EK, Buchwald H (1993) Natural history of atherosclerosis and hypercholesterolemia in heterozygous WHHL (WHHL-Hh) rabbits. I. The effects of aging and gender on plasma lipids and lipoproteins. J Lab Clin Med 121:97-102
11. Falk E, Prediman KS, Fuster V (1995) Coronary plaque disruption. Circulation 92:657-671
12. Franceschini G, Sirtori M, Vaccarino V (1989) Mechanims of HDL reduction after Probucol. Changes in HDL subtractions and increased reverse cholesterol ester transfer. Arteriosclerosis 9:462-469
13. Furberg CD, Byington RP, Crouse JR, Espeland MA (1994) Pravastatin, lipids and major coronary events. Am J Cardiol 73:1133-1134
14. Fuster V, Badimon L, Badimon JJ, Chesebro JH (1992) The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med 326:242-250, 310-318
15. Goldstein JL, Kita T, Brown MS (1983) Defective lipoprotein receptors and atherosclerosis. Lessons from an animal counterpart of familial hypercholesterolemia. N Engl J Med 309:288-297
16. Kita T, Nagano Y, Yokode M, et al (1987) Probucol prevents the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbit, an animal model for familal hypercholesterolemia. Proc Natl Acad Sci USA 84:5928-5931
17. Kleinveld HA, Demacker PN, De Haan AF, Stalenhoef AF (1993) Decreased in vitro oxidiability of low-density lipoprotein in hypercholesterolemic patients treated with 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors. Eur J Clin Invest 23:289-295
18. LaRosa JC, Cleeman JI (1992) Cholesterol lowering as a treatment for established coronary heart disease. Circulation 85:1229-1235
19. Levine GN, Keaney JF, Vita JA (1995) Cholesterol reduction in cardiovascular disease. Clinical benefits and possible mechanisms. N Engl J Med 332:512-521
20. O'Brien K, Nagano Y, Gown A, Kita T, Chait A (1991) Probucol treatment affects the cellular composition but not anti-oxidized low density lipoprotein immunoreactivity of plaques from Watanabe heritable hyperlipidemic rabbits. Arterioscler Thromb 11:751-759
21. Parthasarathy S, Young SG, Witztum JL, Pittman RC, Steinberg D (1986) Probucol inhibits oxidative modification of low density lipoprotein. J Clin Invest 77:641-644
22. Pitt B, Mancini GBJ, Ellis SG, Rosman HS, McGovern ME (1994) Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC 1) (abstract). J Am Coll Cardiol 131A:739-742
23. Pravastatin Multinational Study Group for Cardiac Risk Patients Effects of pravastatin in patients with serum total cholesterol levels from 5.2 to 7.8 mmol/liter (200 to 300 mg/dl) plus two additional risk factors. Am J Cardiol 72:1031-1037
24. Ross R (1993) Atherosclerosis: a defense mechanism gone awry. Am J Pathol 143:987-1002
25. Saito Y, Goto Y, Nakaya N, et al. (1988) Dose-dependent hypolipidemic effect of an inhibitor of HMG-CoA reductase, pravastatin (CS-514), in hypercholesterolemic subjects. A double blind test. Atherosclerosis 72:205-211
26. Saku K, Zhang B, Hirata K, et al (1993) Combined therapy with probucol and pravastatin in hypercholesterolemia. One year follow-up study. Eur J Clin Pharmacol 44:535-539
27. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, Macfarlane PW, McKillop JH, Packard CJ for the WOSCPSG (1995) Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 333:1301-1307
28. Shiomi M, Ito T, Tsukada T, et al (1995) Reduction of serum cholesterol levels alters lesional composition of atherosclerotic plaques. Effect of pravastatin sodium on atherosclerosis in mature WHHL rabbits. Circulation 15:1938-1944
29. Stary HC (1992) Composition and classification of human atherosclerotic lesions. Virchows Arch [A] 421:277-290
30. Stary HC, Chandler AB, Glagov S et al. (1994) A definition of initial, fatty streak, and intermediate lesions of atherosclerosis. A report from the committee on vascular lesions of the Council on Atherosclerosis, American Heart Association. Arterioscler Thromb 14:840-856
31. Steinberg D (1995) The oxidative modification hypothesis of atherogenesis: strengths and weaknesses. In: Woodford FP, Davignon J, Sniderman A (eds) Atherosclerosis X. Proceedings of the 10th International Symposium on Atherosclerosis, Montreal. Excerpta Medica, Amsterdam, pp 25-29
32. Steinberg D, Parthasarathy S, Carew TE (1988) In vivo inhibition of foam cell development by probucol in Watanabe rabbits. Am J Cardiol 62:6B-12B
33. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witzthum JL (1989) Beyond cholesterol: Modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 320:915-924
34. Watanabe Y, Ito T, Shiomi M, et al (1988) Preventive effect of pravastatin sodium, a potent inhibitor of 3-hydroxy-3-methyl-glutaryl coenzyme A reductase, on coronary atherosclerosis and xanthoma in WHHL rabbits. Biochim Biophys Acta 960:294-302
35. Yamamoto A, Yokoyama S, Yamamura T (1988) Escape phenomenon occurs by lowering cholesterol with a hydroxymethyl-glutaryl coenzyme A (HMG-CoA) reductase inhibitor in patients with familial hypercholesterolemia. Atherosclerosis 71:257-260